Turing to Discount Anti-Parasitic Drug as Much as 50%
November 24 2015 - 8:30PM
Dow Jones News
Turing Pharmaceuticals AG, which drew the ire of patient groups
and politicians after raising the price of an anti-parasite tablet
more than 50-fold, said it will discount the drug as much as 50% to
hospitals and take other steps to help patients afford the
cost.
Privately held Turing bought the U.S. rights to the drug,
Daraprim, in August and raised the price to $750 a tablet, from
$13.50. The amount of the discount Turing announced on Tuesday will
depend on how much of the drug hospitals use. Even at the full 50%
off, however, the drug will still cost far more than before Turing
increased its price.
In addition, health insurers would have to pick up the tab for
patients who keep taking the drug after leaving the hospital.
Though Turing said it was participating in federal and state
health-insurance programs such as Medicaid, in which the drug would
cost as low as $1 per 100-pill bottle.
"We pledge that no patient needing Daraprim will ever be denied
access," said Nancy Retzlaff, Turing's chief commercial
officer.
How much Turing would cut the cost of Daraprim has been a
question since the company and Chief Executive Martin Shkreli drew
criticism for the price increase from patient advocates and
politicians including Democratic presidential candidates Hillary
Clinton and Bernie Sanders.
The Wall Street Journal reported in September that Turing would
cut the price, but was still working out by how much. The Journal
reported last week on Turing's discounting plans.
Daraprim is a half-century-old drug that treats an infection
from the toxoplasma parasite that can threaten the lives of HIV
patients, pregnant women and others with weakened immune systems.
Each year, more than a million people in the U.S. deal with the
infections.
Turing's price rise became a featured example of the massive
price increases that several pharmaceutical companies have taken,
even though the companies hadn't done the research behind the
medicine. Democrats in Congress have launched investigations.
A nine-month-old startup founded by hedge-fund manager Mr.
Shkreli, Turing countered that it was using the higher revenue from
the Daraprim price increase to fund its own drug
research-and-development programs. Turing said Tuesday it was using
some of the revenue from Daraprim to fund research into a new and
better treatment.
"This is part of Turing's commitment to invest at least 60% of
its revenues for the foreseeable future into research and
development of innovative therapies, primarily for rare and
neglected diseases," a company spokesman said.
Turing has started a second round of financing, aiming to raise
$50 million to $100 million and valuing the company at $500
million, according to a person familiar with the matter.
Aside from offering discounts to hospitals, Turing also will
start selling bottles containing 30 tablets, which would help
hospitals that don't use a lot of the pills and don't go through
all of the 100 tablet bottles that have been on sale.
In addition, Turing said it will start giving out free samples
to doctors for starting patients on the drug.
The company also pledged to cut the out-of-pocket costs of the
drug to no more than $10 a prescription if commercially insured
patients use its copay assistance program. And Turing said it was
contributing to a charity that could help Medicare patients afford
their out-of-pocket costs.
The company said it will give the drug free of charge to
patients whose incomes are at or below 500% of the poverty
line.
Access Investor Kit for "CitiGroup Inc"
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US1729674242
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 24, 2015 20:15 ET (01:15 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Citigroup (NYSE:C)
Historical Stock Chart
From Aug 2024 to Sep 2024
Citigroup (NYSE:C)
Historical Stock Chart
From Sep 2023 to Sep 2024